Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?
作者信息
Bahçecíoğlu Ömer Faruk, Gök Selim, Durmuş Mefküre
机构信息
Clinical Pharmacy, Inonu University, Malatya, Turkey
Clinical Pharmacy, Inonu University, Malatya, Turkey.
出版信息
Eur J Hosp Pharm. 2021 Mar;28(2):e6. doi: 10.1136/ejhpharm-2021-002680. Epub 2021 Jan 20.
Abstract
摘要
相似文献
1
Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?将瑞德西韦与P-糖蛋白和CYP3A4联合抑制剂联合使用是否安全？
Eur J Hosp Pharm. 2021 Mar;28(2):e6. doi: 10.1136/ejhpharm-2021-002680. Epub 2021 Jan 20.
2
Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors.新型冠状病毒疾病 2019 患者的药物性肝损伤：瑞德西韦与 P-糖蛋白抑制剂的潜在相互作用。
Clin Infect Dis. 2021 Apr 8;72(7):1256-1258. doi: 10.1093/cid/ciaa883.
3
Remdesivir for patients with COVID-19.瑞德西韦用于治疗新冠肺炎患者。
CMAJ. 2021 Jan 25;193(4):E125. doi: 10.1503/cmaj.202505. Epub 2021 Jan 6.
4
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters.美国食品和药物管理局批准的药物考比司他与瑞德西韦协同抑制 SARS-CoV-2 复制，降低叙利亚仓鼠的病毒滴度和疾病进展。
mBio. 2022 Apr 26;13(2):e0370521. doi: 10.1128/mbio.03705-21. Epub 2022 Mar 1.
5
Remdesivir as a broad-spectrum antiviral drug against COVID-19.瑞德西韦作为一种广谱抗 COVID-19 病毒药物。
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):541-548. doi: 10.26355/eurrev_202101_24426.
6
[Not Available].[无可用内容]。
CMAJ. 2021 Apr 6;193(14):E495-E496. doi: 10.1503/cmaj.202505-f.
7
Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.瑞德西韦和法匹拉韦治疗 COVID-19 的心血管注意事项。
Cardiovasc Hematol Disord Drug Targets. 2021;21(2):88-90. doi: 10.2174/1871529X21666210812103535.
8
Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.严重免疫功能低下患者接受多疗程瑞德西韦治疗后，SARS-CoV-2 持续复制。
Int J Infect Dis. 2021 Mar;104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21.
9
Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case-noncase study.2019冠状病毒病中作为瑞德西韦严重药物不良反应的肾脏疾病：一项回顾性病例对照研究
Kidney Int. 2021 May;99(5):1235-1236. doi: 10.1016/j.kint.2021.02.015. Epub 2021 Feb 26.
10
Sinus Bradycardia in a Pediatric Patient Treated With Remdesivir for Acute Coronavirus Disease 2019: A Case Report and a Review of the Literature.瑞德西韦治疗儿童急性 2019 冠状病毒病合并窦性心动过缓：病例报告及文献复习。
J Pediatric Infect Dis Soc. 2021 Oct 27;10(9):926-929. doi: 10.1093/jpids/piab029.
引用本文的文献
1
Neurological Complications of COVID-19: Underlying Mechanisms and Management.新型冠状病毒肺炎相关神经系统并发症：发病机制与治疗。
Int J Mol Sci. 2021 Apr 15;22(8):4081. doi: 10.3390/ijms22084081.
本文引用的文献
1
Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective.瑞德西韦与肺部药物的潜在相互作用：从新冠肺炎角度看
SN Compr Clin Med. 2020;2(10):1707-1708. doi: 10.1007/s42399-020-00462-2. Epub 2020 Aug 21.
2
Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors.新型冠状病毒疾病 2019 患者的药物性肝损伤：瑞德西韦与 P-糖蛋白抑制剂的潜在相互作用。
Clin Infect Dis. 2021 Apr 8;72(7):1256-1258. doi: 10.1093/cid/ciaa883.
3
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.瑞德西韦是一种直接作用的抗病毒药物，能高效抑制严重急性呼吸综合征冠状病毒 2 的 RNA 依赖性 RNA 聚合酶。
J Biol Chem. 2020 May 15;295(20):6785-6797. doi: 10.1074/jbc.RA120.013679. Epub 2020 Apr 13.
4
P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms.基于细胞色素P450的胺碘酮及其代谢产物的药物相互作用：抑制机制的多样性
Drug Metab Dispos. 2015 Nov;43(11):1661-9. doi: 10.1124/dmd.115.065623. Epub 2015 Aug 21.
Zotero 插件